In addition, studies have shown that intravenous injection of TLR9 agonists nanoparticles can detect tumor microenvironment, generate localized immune activation and release the dead tumor cells into the circulation, which are then taken up by the antigen-presenting cells to trigger an anti-tumor immune reaction by stimulating tumor antigen-specific CD8 T cell (36). The gene discussed is TLR9; the disease is neoplasm.